MétaCan
Menu
← Back to cohort
Record W4411418475 · doi:10.1016/j.ard.2025.05.216

OP0204 LUPUS DAMAGE INDEX REVISION – ITEM GENERATION AND REDUCTION PHASE

2025· article· en· W4411418475 on OpenAlexaff
Burak Kundakci, Megan R.W. Barber, Ann E. Clarke, Stanley R. Johnson, Ian N Bruce

Bibliographic record

VenueAnnals of the Rheumatic Diseases · 2025
Typearticle
Languageen
FieldMedicine
TopicSystemic Lupus Erythematosus Research
Canadian institutionsToronto Western HospitalMount Sinai HospitalUniversity of Calgary
Fundersnot available
KeywordsMedicineSystemic lupus erythematosusReduction (mathematics)Index (typography)Internal medicineDiseaseWorld Wide Web

Abstract

fetched live from OpenAlex

Background: The Systemic Lupus International Collaborating Clinics ( SLICC)/ American College of Rheumatology (ACR) Damage Index for Systemic Lupus Erythematosus (SLE) (SDI) [1] is a robust instrument, but has limitations in terms of missing items, limited usefulness in paediatric patients, and outdated item definitions[2]. SLICC, ACR and the Lupus Foundation of America (LFA) collaboratively embarked on a project to develop a revised SLE Damage Index using data-driven and expert/patient consensus-based approaches. The methodological approach includes 5 phases: updating the construct of damage, item generation, item reduction, item definition and weighting/threshold determination, and the assessment of validation and reliability. In phase I, qualitative methods were used to define the modern construct of damage in SLE [3]. Objectives: To report the item generation and reduction phases for developing a revised SDI. Methods: Item generation began with a comprehensive literature review and an initial Delphi exercise of international SLE experts. Item reduction involved conducting two additional Delphi rounds, where items with a median score of ≤4 out of 9 were excluded (1 = not at all appropriate and 9=completely appropriate). Items that were redundant, did not reflect the damage construct, were excessively rare, or were not feasible to assess were also removed. The expert organ domain groups defined the remaining items and suggested severity gradations for relevant items. Results: A panel of 146 individuals from 35 countries, broadly reflecting the lupus research and patient community, was established. The literature review generated 4 (1.8%) unique items, while 103 (46.8%) unique items were generated in the Delphi process, and 113 (51.4%) items overlapped in both processes. After the second Delphi round, Delphi participants suggested an additional 6 unique items, giving a total of 226 items. Thirty-six items scoring ≤4 out of 9 were removed. A further 126 items were removed due to redundancy, inadequate reflection of damage construct, association with lupus disease activity, rarity, or limited feasibility for assessment. This process excluded all items in two newly proposed organ domains including haematology and reproduction/pregnancy, reducing the number of organ domains to 12. The expert organ domain groups reviewed the candidate items, leading to a final total of 38 items. Figure 1 shows the number of candidate items identified at different stages of Phase II/III during revised SDI development. Figure 1Number of candidate items identified at different stages of Phase II/III during revised SDI development Eleven items from the previous SDI, including chronic peritonitis, muscle atrophy, and osteomyelitis, were removed. Several new items were proposed, such as growth failure/reduced final height and adrenal insufficiency. Moreover, 13 items had proposed gradings of severity (Table 1). For example, ischaemic heart disease is proposed to be graded as follows: Grade 1: asymptomatic ischaemia on testing, Grade 2: symptomatic angina with confirmatory tests Grade 3: myocardial infarction (clinical presentation and confirmatory tests) and Grade 4: multiple myocardial infarctions and/or coronary artery bypass grafting. Similarly, kidney function impairment is proposed to be graded according to Kidney Disease Improving Global Outcomes (KDIGO) categories of glomerular filtration rate (GFR). Grade 0 -GFR ≥60 mL/min/1.73 m², Grade 1 -GFR 30-59 mL/min/1.73 m², Grade 2 - GFR 15-29 mL/min/1.73 m², and Grade 3 GFR <15 mL/min/1.73 m². Conclusion: The item generation and reduction phases resulted in 38 candidate items to be taken forward to the next stages. Grading damage items is possible for 34.2% of proposed items in a new revised damage index. This offers a more detailed and clinically relevant assessment of organ damage in SLE patients. It reflects current evidence based medical practice and is likely to improve sensitivity of the index in SLE populations. Further validation in cohorts and consideration of weighting of grades across clinical organ systems is now underway. REFERENCES: [1] Gladman, Dafna, et al. "The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 39.3 (1996): 363-369. [2] Barber, Megan RW, et al. "Evolving concepts in systemic lupus erythematosus damage assessment." Nature Reviews Rheumatology 17.6 (2021): 307-308. [3] Johnson, Sindhu R., et al. "Evaluating the construct of damage in systemic lupus erythematosus." Arthritis Care & Research 75.5 (2023): 998-1006. Table 1Items suggested for gradation in the revised damage index..ItemsGradesStroke1,2,3Cognitive impairment1,2Ocular damage1,2,3,4,5Kidney function impairment1,2,3Renal biopsy findings1,2Pulmonary fibrosis1,2Cardiomyopathy1,2,3,4Ischaemic heart disease1,2,3,4Valve vegetations/thickening1,2,3Pulmonary hypertension1,2Scarring chronic alopecia1,2,3Cutaneous scarring or atrophy1,2Dyspigmentation1,2 Acknowledgements: We thank the revised SDI collaborators for their valuable input. The project is supported by LFA, SLICC and ACR. Disclosure of Interests: Burak Kundakci: None declared, Megan Barber AbbVie, AstraZeneca, GSK, Janssen, Sanofi-Genzyme, Ann E. Clarke AstraZeneca, GSK, BMS, Novartis, Roche, GSK, Sindhu R. Johnson: None declared, Ian Bruce Astra Zeneca, Janssen, GSK, Novartis, Astra Zeneca, Janssen, GSK, Novartis, Takeda, BMS, Grants to Institution from Astra Zeneca, Janssen, GSK, Otsuka, on behalf of the Revised Systemic Lupus Erythematosus (SLE) Organ Damage Index (SDI) Collaborators: None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.048
metaresearch head score (Gemma)0.093
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.048
Threshold uncertainty score0.255

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0480.093
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0040.004
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0030.003
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0310.010

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.386
Teacher spread0.329 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of the Rheumatic Diseases→Same topicSystemic Lupus Erythematosus Research→French-language works237,207→